Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozuriftamab vedotin in recurrent or metastatic head and neck squamous cell carcinoma
NCT05271604Phase 2Completed
- Sponsor
- BioAtla
- Start
- Dec 2022
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of ozuriftamab vedotin in squamous cell carcinoma of the head and neck (HNSCC) (6 cohorts), sponsored by BioAtla. Primary endpoints: Objective Response Rate at 24 months and Adverse Events at 24 months. Started Dec 2022; status: completed.
02
Drugs
ozuriftamab vedotin
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05271604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05271604.